Dermatology · Chromoblastomycosis

Long-Term Health and Monitoring

At a Glance

Chromoblastomycosis can return months or years after treatment, and long-standing scars can rarely develop skin cancer. Regular clinician visits and lifelong self-checks help detect relapse, suspicious scar changes, and lasting swelling early.

Reaching the end of treatment for chromoblastomycosis is a major milestone, but it is not the end of your journey. Because this fungus is exceptionally persistent and can hide deep within scar tissue, long-term monitoring is essential to ensure the infection does not return and to catch any late-stage complications early ^[1]^[2].

The Risk of Recurrence

Even when your skin looks clear (clinical cure) and tests temporarily show no fungus (mycological cure), there is a significant risk of relapse ^[3].

Timing of Relapse: Relapses can occur months or even years after treatment has ended ^[1]^[3].
Relapse vs. New Infection: It is important to distinguish between a true relapse (the original fungus waking up in the scar tissue) and a new environmental inoculation (getting poked by a new splinter). Both require prompt assessment.
What to Watch For: New, small reddish bumps (papules) or crusty areas appearing at the site of your original lesion or along the edges of a surgical scar should be reported to your doctor immediately ^[4]^[5].

Monitoring for Skin Cancer (SCC)

The most serious long-term risk of chromoblastomycosis is the development of a type of skin cancer called squamous cell carcinoma (SCC) ^[2]. This does not happen to everyone, but it is an important risk for those who have had the infection.

The Timeline: Chronic inflammation and scarring can cause the skin cells to change over time (sometimes called a Marjolin’s ulcer). While SCC risk increases significantly in long-standing disease (often reported in patients who have had the infection for many years), no duration is completely “safe,” and every patient requires vigilance ^[6]^[2].
Warning Signs: You should seek an evaluation for a biopsy if any part of your scar develops:
- Rapid focal growth or a new, firm, “fleshy” lump ^[6]^[7].
- A persistent ulcer that bleeds easily or has “everted” (rolled-out) edges ^[6].
- A thick, warty, white or discolored plaque that looks very different from the rest of the scar ^[8]^[7].

Managing Permanent Changes

For many survivors, the infection leaves behind permanent changes to the skin and underlying tissue.

Fibrosis and Scarring: The body’s immune response to the fungus often creates thick, tough fibrosis (scar tissue) ^[9]. This can make the skin feel tight and limit your range of motion if near a joint ^[10]^[11].
Chronic Lymphedema: Damage to the lymph vessels can lead to permanent swelling of the limb ^[12]^[13]. Managing this requires professional guidance:
- Compression Therapy: This must be prescribed after a clinician assesses your circulation, checks garment fitting, and rules out active acute infection (cellulitis) ^[12]. Do not select a compression grade on your own.
- Manual Lymphatic Drainage: A specialized form of massage. This should be provided by a trained lymphedema therapist. Pause therapy and seek urgent advice if the limb becomes hot, red, suddenly painful, or rapidly more swollen.

Your Individualized Follow-Up Plan

There is no single, universal follow-up schedule. Your appointments and any necessary repeat biopsies or cultures will depend on your specific treatment, exam findings, and specialist access. Obtain a written follow-up plan from your dermatologist or infectious disease doctor.

An Example Follow-Up Framework (Your specific plan may vary):

Timeframe	Example Actions
First Year Post-Treatment	Routine clinical exams (e.g., every 3 to 6 months) to inspect the healed skin. Targeted testing only if symptoms return ^[14]^[5].
Long-Term	Regular check-ups (e.g., annual) to monitor for late relapse and assess for thickening of the scar ^[15]^[2].
Lifelong Self-Monitoring	Biopsies are not a routine test in an asymptomatic scar, but any suspicious focal change or new bump warrants immediate clinical evaluation ^[16]^[2].

Consider keeping a simple self-monitoring checklist at home to record lesion size, changes in swelling, or new symptoms, which you can bring to your appointments.

Common questions in this guide

Can chromoblastomycosis come back after treatment?

Yes. Chromoblastomycosis can relapse months or years after treatment, even when the skin looks clear and tests temporarily show no fungus. New bumps, crusting, or changes near the old lesion or surgical scar should be assessed promptly.

What skin changes after chromoblastomycosis need an urgent evaluation?

Ask a clinician to examine a scar if it develops a rapidly growing firm lump, an ulcer that persists or bleeds easily, rolled-out edges, or a thick, warty, or discolored plaque. These changes can signal squamous cell carcinoma and may require a biopsy.

How often should I have follow-up visits after chromoblastomycosis treatment?

There is no schedule that fits everyone. A clinician may recommend exams every 3 to 6 months during the first year and then longer-term visits, such as annually, based on your treatment, examination findings, and access to specialists. Ask for a written plan.

How should I monitor my old chromoblastomycosis scar at home?

Check the affected skin and limb regularly, ideally monthly, for new bumps, crusting, bleeding, ulceration, thickening, changes in color or texture, and increasing swelling. Record changes in lesion size or limb size and bring the information to appointments. Routine biopsy is not needed when a scar has no suspicious changes, but new focal changes need prompt assessment.

Is compression therapy safe for swelling after chromoblastomycosis?

Compression therapy should be used only after a clinician checks circulation, fits the garment, and rules out an active infection such as cellulitis. Do not choose the compression strength yourself. If the limb becomes hot, red, suddenly painful, or rapidly more swollen, pause manual lymphatic drainage and seek urgent medical advice.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Chromomycosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.How frequently should I schedule follow-up appointments now that my treatment is finished?
2.Based on the amount of scarring I have, what specific changes in my skin should I look for that might signal a recurrence or a more serious change?
3.Can you refer me to a lymphedema specialist or a physical therapist who can help me manage the swelling and stiffness in my limb?
4.How long after my 'clinical cure' will you continue to perform clinical exams to ensure a 'mycological cure'?
5.Is compression therapy safe for me given my circulation, and if so, what grade of compression garment do I need?

References (16)

1
[Management of chromoblastomycosis, a challenge for limited-resource countries such as Madagascar].
Sendrasoa FA, Rakotoarisaona MF, Ranaivo IM, et al.
Annales de dermatologie et de venereologie 2020; (147(5)):377-382 doi:10.1016/j.annder.2020.01.018.
PMID: 32220474
2
Squamous cell carcinoma in chronic lesions of recalcitrant chromoblastomycosis. Study of ten patients treated at the Dermatological Center of Yucatán, Mexico.
Calderón Quiroz ER, Torres Guerrero E, Proy Trujillo H, et al.
Anais brasileiros de dermatologia 2026; (101(4)):501372 doi:10.1016/j.abd.2026.501372.
PMID: 42235130
3
Exophiala psychrophila: A new agent of chromoblastomycosis.
Garzon LM, Rueda LJ, Celis AM, et al.
Medical mycology case reports 2019; (23()):31-33 doi:10.1016/j.mmcr.2018.10.001.
PMID: 30533349
4
A Case of Chromoblastomycosis Caused by Knufia epidermidis Presenting as Multiple Dark Brown Papules in the Nasal Area.
Akimoto R, Nakamura K, Fukuda T
Medical mycology journal 2025; (66(4)):171-175 doi:10.3314/mmj.25-00015.
PMID: 41320316
5
A Case of Recurrent Chromoblastomycosis Treated with Multiple Surgical Management Options.
Kelly M, Williams C, Miller R
Dermatopathology (Basel, Switzerland) 2026; (13(1)) doi:10.3390/dermatopathology13010010.
PMID: 41892077
6
Predisposing factors and histopathological variants of cutaneous squamous cell carcinoma: Experience from a North Indian teaching hospital.
Khullar G, Saikia UN, De D, et al.
Indian journal of dermatology, venereology and leprology 2016; (82(3)):273-8 doi:10.4103/0378-6323.168936.
PMID: 27088928
7
Chromoblastomycosis evolving to sarcomatoid squamous cell carcinoma: A case report.
Belda Junior W, Criado PR, Casteleti P, Domingues Passero LF
Dermatology reports 2021; (13(2)):9009 doi:10.4081/dr.2021.9009.
PMID: 34497696
8
Chromoblastomycosis Leading to Squamous Cell Carcinoma: An Overlooked Outcome of a Neglected Tropical Disease.
Smith DJ, Grijsen ML, Chincha O, et al.
Cutis 2026; (117(5)):143-145 doi:10.12788/cutis.1392.
PMID: 42497337
9
Neutrophil extracellular traps (NETs) and Th-2 dominant immune responses in chronic granulomatous chromobalstomycosis.
Huang H, Li M, Luo M, et al.
Medical mycology 2024; (62(2)) doi:10.1093/mmy/myae008.
PMID: 38318638
10
Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years.
Guevara A, Siqueira NP, Nery AF, et al.
Medical mycology 2021; (60(1)) doi:10.1093/mmy/myab062.
PMID: 34637525
11
Quality of Life, Disability, and Fungal Neglected Tropical Diseases.
Cavanaugh AM, Ribeiro Dos Santos A, Freitas DFS, et al.
Current fungal infection reports 2025; (19(1)) doi:10.1007/s12281-025-00503-0.
PMID: 40927623
12
Chromoblastomycosis and phaeohyphomycotic abscess-associated hospitalizations, United States, 2016-2021.
Smith DJ, Benedict K, Lockhart SR, Revankar SG
PLoS neglected tropical diseases 2025; (19(9)):e0013499 doi:10.1371/journal.pntd.0013499.
PMID: 40906775
13
Chromoblastomycosis is curable with DAT therapy (debulking, intralesional amphotericin B, oral terbinafine); case series of 16 patients.
Ranawaka RR, Abeywickrama V
Indian journal of pharmacology 2024; (56(6)):437-439 doi:10.4103/ijp.ijp_397_24.
PMID: 39973833
14
Triple therapy approach for treating chromoblastomycosis in a Lebanese patient.
Khodeir J, Ohanian P, Megarbane HAR
Clinical case reports 2024; (12(10)):e9392 doi:10.1002/ccr3.9392.
PMID: 39355768
15
[Long-pulsed 1064 nm Nd: YAG laser combined with terbinafine against chromoblastomycosis caused by Fonsecaea nubica and the effect of laser therapy in a Wistar rat model].
Luo J, Feng P, Hu Y, et al.
Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2019; (39(6)):712-717 doi:10.12122/j.issn.1673-4254.2019.06.13.
PMID: 31270051
16
Squamous cell carcinoma derived from chronic chromoblastomycosis in Brazil.
Azevedo CM, Marques SG, Santos DW, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (60(10)):1500-4 doi:10.1093/cid/civ104.
PMID: 25681378

This page is for informational purposes only and does not constitute medical advice. Your dermatologist or infectious disease doctor should tailor follow-up, biopsy decisions, and lymphedema care to your situation.

Guide Contents